Skip to content
University of Oxford
-
Oxford launches first human trial of Bundibugyo Ebola vaccine as DRC outbreak intensifies
The BD-Ebov trial, which is being conducted in Oxford, will evaluate the safety, tolerability and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged between 18 and 55 years.
-
CEPI pledges US$60M to fast-track Bundibugyo Ebola vaccines from Moderna, Oxford, and IAVI
The funding will support three promising vaccine candidates being developed by Moderna, the University of Oxford in partnership with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).